Navigation Links
Enigma Diagnostics Announces the Opening of a United States Office
Date:12/2/2008

PORTON DOWN, England and SAN FRANCISCO, Dec. 2 /PRNewswire/ --Enigma Diagnostics, the decentralized and point-of-care molecular diagnostics company, announced today the opening of a new U.S. office in San Francisco and the appointment of Chris Melancon as Vice President, Business Development.

The San Francisco office opened on December 1 and is Enigma's first overseas facility established to commercialize Enigma's range of rapid diagnostic instrument systems. Enigma's first product, the Enigma Field Laboratory (FL), was launched in November, and is a fully automated, real-time PCR (polymerase chain reaction) detection system designed for in-field testing by veterinarians, first responders and military personnel.

Chris Melancon will lead the new office and joins Enigma with more than 16 years experience in life sciences and information technology industries, including senior positions at Applied Biosystems and Siebel Systems, a division of Oracle Corporation. His work in emerging markets included biological and influenza surveillance and pathogen detection.

During his three-year tenure at ABI, Chris managed the large scale PCR reagents business for anthrax testing at U.S. Postal Service facilities and commercialized additional pathogen detection kits for European Union customers. He is a graduate of the U.S. Military Academy at West Point and Tulane University's Freeman School of Business.

"The opening of the San Francisco office and Chris' appointment underpins our commitment to a U.S. commercialization strategy as we expand our operations internationally. We are very pleased to have Chris with his proven track record join Enigma at this important stage of our growth," stated John McKinley, Chairman of Enigma Diagnostics.

    Contacts

    UK Contact:
    Enigma Diagnostics
    Deborah Cordingley
    deborah.cordingley@enigmadiagnostics.com
    +44 1980 590131

    U.S. Contacts:
    Richard Lewis Communications, Inc.
    212-827-0020
    Megan Dubrowski - Media
    mdubrowski@rlcinc.com
    Cecelia Heer - Investors
    cheer@rlcinc.com

About Enigma Diagnostics Limited

Enigma Diagnostics Limited is a private UK based company specializing in developing the next generation of rapid molecular diagnostic instrument platforms for decentralized and point-of-care settings.

Enigma's innovative and proprietary technology combines the speed and sensitivity of real-time PCR (polymerase chain reaction) with the simplicity needed for field-based, decentralised and point-of-care tests providing results from a raw sample in less than 45 minutes.

The Company is targeting a number of multi-billion dollar markets, core among which are the Clinical and high value Applied Markets. Enigma's commercialization strategy is to maximise revenues from a continuous flow of market leading rapid diagnostic point-of care and in-field instrument and assay platforms, derived from its broad Intellectual Property portfolio of issued and filed patents. Enigma will partner with market leaders where global penetration of markets is required and where appropriate will build an in-house sales and marketing capability to direct distribution of its products.

Enigma has an exclusive license from the Defence Science Technology Laboratory to a portfolio of patents, which represent over 15 years of UK Ministry of Defence funded research and has licences from Applied Biosystems and Celera Licences for the commercialization of real-time PCR instruments. Enigma's R&D activities have generated a portfolio of over 50 plus worldwide patent families dedicated to real-time PCR and wider molecular technologies. Many of these patents are granted across a range of core commercial territories including U.S., EU and Japan with more extensive filing and grants across a number of other key territories.

For more information visit www.enigmadiagnostics.com


'/>"/>
SOURCE Enigma Diagnostics Limited
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Enigma Diagnostics Announces a European Commission Award of EUR3 Million to Fund the Development of a Point of Care Platform for the Rapid Diagnosis of Influenza Infections
2. Enigma Diagnostics to Develop Clinical Diagnostics Platform for UK National Chlamydia Screening Programme
3. Enigma Signs Real-Time PCR Licences With Applera
4. Enigma Diagnostics Announces an Award of GBP 1.8 Million From UK Government
5. Enigma Diagnostics Announces Patent Licence With Applied Biosystems
6. Strategic Diagnostics to Present at Two Upcoming Investor Conferences
7. Strategic Diagnostics Updates Roth Conference Presentation Time
8. Alliance for Medical Devices, Instrumentation and Diagnostics formed between Fraunhofer Center for Manufacturing Innovation and Boston University
9. Rosetta Genomics to Present at the American Association of Cancer Research (AACR) "Molecular Diagnostics in Cancer Therapeutic Development" Conference
10. Indivumed Supports Roche Diagnostics With Immunohistochemistry Services and Clinical Specimens for Biomarker Discovery and Drug Development
11. Quest Diagnostics to Speak at the 2007 UBS Global Life Sciences Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)...   Biocept, Inc . (NASDAQ: ... actionable liquid biopsy tests to improve the management ... its Target Selectorâ„¢ Circulating Tumor Cell platform demonstrated ... of actionable biomarkers in patients with metastatic breast ... Cannon Research Institute (SCRI), the research arm of ...
(Date:12/7/2016)... ... December 07, 2016 , ... Huffman Engineering, Inc. , ... Wonderware Certified System Integrator Partner. Huffman Engineering is the only Nebraska-based company ... System Integrator Partner certification gives customers confidence that our engineers are fully trained ...
(Date:12/7/2016)... CALGARY , Dec. 7, 2016 /PRNewswire/ - Zenith Capital Corp. ... update that will be presented at the Company,s Annual and ... Meeting of Shareholders will take place on Thursday, December 15, ... Ross Glenn Hall (Room EC1040), 4825 Mount Royal Gate ... am (MST). A notice of meeting and management information circular, ...
(Date:12/7/2016)... The report "Acrylic Processing Aid Market by Polymer Type (PVC), Fabrication ... - Global Forecast to 2026", published by MarketsandMarkets, the global market size was ... by 2026, registering an of CAGR of 6.2% between 2016 and 2026. ... ... MarketsandMarkets Logo ...
Breaking Biology Technology:
(Date:12/7/2016)... , Dec. 7, 2016   Veridium ... announced the appointment of new CEO James ... executive with decades of experience, has served in ... Cisco, where he specialized in expanding a pipeline ... technology portfolios. He most recently served as managing ...
(Date:12/6/2016)... 2016 Securus Technologies, a leading provider ... public safety, investigation, corrections and monitoring, and the ... five (5) year funding commitment by Securus to ... rehabilitation and reentry support to more inmates and ... 2004, the Prison Entrepreneurship Program (PEP) is an ...
(Date:12/2/2016)...   SoftServe , a global digital technology ... electrocardiogram (ECG) biosensor analysis system for continuous driver ... The smart system ensures device-to-device communication between ECG ... mobile devices to easily ,recognize, and monitor users ... technology advances, so too must the security systems ...
Breaking Biology News(10 mins):